Thymosin alpha 1: Past clinical experience and future promise

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 130-135

  Tuthill, Cynthia ^a   Rios, Israel ^a   McBeath, Randy ^a  

^a SciClone Pharmaceuticals Inc   (United States)

Author keywords

Cancer; Clinical trial; Hepatitis B; Thymosin; Vaccine enhancer

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; DACARBAZINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; THYMOSIN ALPHA1;

ABSENCE OF SIDE EFFECTS; ANTIBODY RESPONSE; CANCER COMBINATION CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFERENCE PAPER; DIGEORGE SYNDROME; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LIVER CELL CARCINOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; TREATMENT RESPONSE;

ANIMALIA;

EID: 77951814048     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05482.x     Document Type: Conference Paper

References (32)

1. Low, T.L. et al. 1979. The chemistry and biology of thymosin. I. Isolation, characterization, and biological activities of thymosin alpha1 and polypeptide beta1 from calf thymus. J. Biol. Chem. 254: 981-986.
2. Low, T.L.K. & A.L. Goldstein 1979. The chemistry and biology of thymosin II. Amino acid sequence analysis of thymosin alpha 1 and polypeptide beta 1. J. Biol. Chem. 254: 987-995.
3. Wang, S.S., R.Makofske,A. Bach & R.B.Merrifield. 1980. Automated solid phase synthesis of thymosin alpha 1. Int. J. Peptide Protein Res. 15: 1-4.
4. Wara, D. & J. Ammann 1978. Thymosin treatment of childrenwith primaryimmunodeficiency disease. Transplant. Proc. 10: 203-209.
5. Wara, D., A. Goldstein, N. Doyle & A. Ammann. 1975. Thymosin activity in patients with cellular immunodeficiency. N. Engl. J. Med. 292: 70-74.
6. Gupta, S., S. Aggarwal & T. Nguyen. 1997. Accelerated spontaneous programmed cell death in lymphocytes in DiGeorge Syndrome. J. Allergy Clin. Immunol. 99: S3(11).
7. Schulof, R.S. et al. 1985. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J. Biol. Response Modif. 4: 147-158.
8. McConnell, L. et al. 1989. Augmentation of influenza antibody levels and reduction in attack rates in elderly subjects by thymosin alpha 1. Gerentologist 29: 188A.
9. Gravenstein, S., W.B. Ershler, S. Drumaskin, et al. 1986. Anti-influenza antibody response: Augmentation in elderly "non-responders" by thymosin alpha 1. Gerontologist 26: 150A.
10. Gravenstein, S. et al. 1989. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J. Am. Geriatr. Soc. 37: 1-8.
11. Shen, S., J. Josselson, C. McRoy, et al. 1987. Effect of thymosin alpha 1 on heptavax-B vaccination among hemodialysis patients. Kidney Int.: 217.
12. Shen, S., J. Josselson, C. McRoy, et al. 1987. Effects of thymosin alpha 1 on peripheral T-cell and Heptavax-B vaccination in previously non-responsive hemodialysis patients. Hepatology 7: 1120.
13. Shen, S.Y. et al. 1990. Age-dependent enhancement of influenza vaccine responses by thymosin in chronic hemodialysis patients. In Biomedical Advances in Aging. A.L. Goldstein, Ed.: Plenum Press. New York.
14. Favalli, C. 1993. Combination therapy in malignant melanoma. In Third International Symposium on Combination Therapies, Houston, TX, p. 12.
15. Lopez, M. et al. 1994. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: Clinical and immunological effects. Ann. Oncol. 5: 741-746.
16. Rasi, G. et al. 2000. Combined treatment with thymosin alpha 1 and low-dose interferon alpha after dacarbazine in advanced melanoma. Melanoma Res. 10: 189-192.
17. Terzoli, E. et al. 1992. Advanced breast cancer treatment with thymosin alpha 1, IFNalpha andepirubicin: Preliminary results. Second International Symposium on Combination Therapies, Acireale, Sicily, Italy. Plenum Press, New York.
18. Terzoli, E. et al. 1992. Combined treatment of advanced breast cancer with epirubicin, thymosin alpha 1 and alpha interferon. Am. Soc. Clin.Oncol. 11: 69.
19. Wolf, G.T. et al. 1989. Prospective randomized trial of thymosin alpha 1 immune reconstitution in patients with advanced head and neck squamous carcinoma: 5 year results. Proc. Am. Assoc. Cancer Res. 30: 261.
20. Basso,N. et al. 1992. Adjuvant chemoimmunotherapy in gastric cancer patients: Pilot study-phase II. Preliminary results. Second International Symposium on Combination Therapies, Acireale, Sicily, Italy. PlenumPress,New York.
21. Stefanini, G.F. et al. 1998. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: A preliminary experience. Hepatogastroenterology 45: 209-215.
22. Venditti, A. et al. 1993. Combination therapy with biological factors and differentiating agents in the treatment of malignant haemopathy. In Third International Symposium on Combination Therapies, Houston, TX.
23. Venditti, A. et al. 1993. Biological response modifiers and differentiating agents inmyelodisplastic syndromes. In Combination therapies I . A.L. Goldstein & E. Garaci, Eds.: Plenum Press, New York.
24. Schiff, E. 1993. Viral hepatitis-1993: An update. Med. Sect. Proc.: 181-193
25. Chan, H.L., J.L. Tang, W. Tam & J.J. Sung. 2001. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: A meta-analysis. Aliment. Pharmacol. Ther. 15: 1899-1905.
26. Saruc, M.,H. Yuceyar,N. Kucukmetin, et al. 2002. Combination thymosin alpha 1 and interferon alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepato-gastroenterology 49: 798-802.
27. Souglu, O., B. Elkabes, S. Sokucu & G. Saner 2001. Thymosin alpha and lamivudine combination therapy in pediatric patients with chronic hepatitis B infection unresponsive to previous treatments: A pilot study. Gut 49: 1639.
28. Dienstag, J.L. et al. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341: 1256-1263.
29. Gilead. 2001. Adefovir Package Insert.
30. Tuthill, C.T. 2007. Issues in pharmaceutical development of thymosin alpha 1 from preclinical studies through marketing. Ann. N.Y. Acad. Sci. 1112: 351-356.
31. Camerini, R. et al. 2007. A large, first-line, randomized, dose-finding, phase II study on thymosin alpha 1 (Ta1) plus dacarbazine (DTIC)with orwitout interferon alpha (IFNa) vs DTIC plus IFNa in stave IVmelanoma. Tumor response and survival results.Am. Soc. Clin.Onocol. Abstract 8535.
32. Gish, R.G., S.C. Gordon, D. Nelson, et al. 2009. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol. Int.